# ENVAFOLIMAB Single-agent Treatment in Patients With Advanced Solid Tumors

Source: https://onco.cc/trials/nct04891198/  
OnCo record `nct04891198` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Envafolimab in advanced solid tumours, run by 3D Medicines (Sichuan) Co., Ltd., now recruiting.

## Summary

ENVAFOLIMAB Single-agent Treatment in Patients With Advanced Solid Tumors is a phase 2 interventional study registered as NCT04891198 by 3D Medicines (Sichuan) Co., Ltd., with 126 participants planned, started 2021-08-06 and due to reach its primary completion in 2027-08-30. Interventions recorded: Envafolimab.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT04891198
- Phase: 2
- Setting: An Open, Single-arm, Multi-center Phase II Clinical Study of ENVAFOLIMAB Single-agent Treatment in Patients With Advanced Solid Tumors
- Sponsor: 3D Medicines (Sichuan) Co., Ltd.
- Enrolled: 126

## Sources

- ClinicalTrials.gov NCT04891198: https://clinicaltrials.gov/study/NCT04891198

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [Envafolimab](https://onco.cc/drugs/envafolimab/)

---
JSON: https://onco.cc/api/v1/entities/nct04891198.json